Tags

Type your tag names separated by a space and hit enter

Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
J Immunol. 1998 Sep 15; 161(6):3186-94.JI

Abstract

Prostate-specific Ag (PSA), which is expressed in a majority of prostate cancers, is a potential target for specific immunotherapy. Previous studies have shown that two 10-mer PSA peptides (designated PSA-1 and PSA-3) selected to conform to human HLA class I-A2 motifs can elicit CTL responses in vitro. A longer PSA peptide (30-mer) designated PSA-OP (oligoepitope peptide), which contains both the PSA-1 and PSA-3 HLA-A2 epitopes and an additional potential CTL epitope (designated PSA-9) for the HLA-class I-A3 allele, was investigated for the ability to induce cytotoxic T cell activity. T cell lines from different HLA-A2 and HLA-A3 donors were established by in vitro stimulation with PSA-OP; the CTL lines lysed PSA-OP as well as PSA-1- or PSA-3-pulsed C1R-A2 cells, and PSA-OP and PSA-9-pulsed C1R-A3 cells, respectively. The CTL lines derived from the PSA-OP peptide also lysed PSA-positive prostate cancer cells. PSA-OP-derived T cell lines also lysed recombinant vaccinia-PSA-infected targets but not targets infected with wild-type vaccinia. PSA-OP did not bind HLA-A2 and HLA-A3 molecules. The decrease in cytotoxicity in the presence of protease inhibitors suggests that the PSA-OP is cleaved into shorter peptides, which in turn can interact with HLA-class I molecules and, as a consequence, induce CTL-mediated lysis. We have also demonstrated that it is possible to induce CTL responses in HLA-A2.1/Kb transgenic mice by immunization with PSA-OP with adjuvant. These studies thus provide evidence that oligopeptides such as PSA-OP may be useful candidates for peptide-based cancer vaccines.

Authors+Show Affiliations

Laboratory of Tumor Immunology and Biology, Division of Basic Science, National Cancer Institute, Bethesda, MD 20892, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9743387

Citation

Correale, P, et al. "Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-specific Antigen (PSA) Employing a PSA Oligoepitope Peptide." Journal of Immunology (Baltimore, Md. : 1950), vol. 161, no. 6, 1998, pp. 3186-94.
Correale P, Walmsley K, Zaremba S, et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol. 1998;161(6):3186-94.
Correale, P., Walmsley, K., Zaremba, S., Zhu, M., Schlom, J., & Tsang, K. Y. (1998). Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. Journal of Immunology (Baltimore, Md. : 1950), 161(6), 3186-94.
Correale P, et al. Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-specific Antigen (PSA) Employing a PSA Oligoepitope Peptide. J Immunol. 1998 Sep 15;161(6):3186-94. PubMed PMID: 9743387.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. AU - Correale,P, AU - Walmsley,K, AU - Zaremba,S, AU - Zhu,M, AU - Schlom,J, AU - Tsang,K Y, PY - 1998/9/22/pubmed PY - 1998/9/22/medline PY - 1998/9/22/entrez SP - 3186 EP - 94 JF - Journal of immunology (Baltimore, Md. : 1950) JO - J. Immunol. VL - 161 IS - 6 N2 - Prostate-specific Ag (PSA), which is expressed in a majority of prostate cancers, is a potential target for specific immunotherapy. Previous studies have shown that two 10-mer PSA peptides (designated PSA-1 and PSA-3) selected to conform to human HLA class I-A2 motifs can elicit CTL responses in vitro. A longer PSA peptide (30-mer) designated PSA-OP (oligoepitope peptide), which contains both the PSA-1 and PSA-3 HLA-A2 epitopes and an additional potential CTL epitope (designated PSA-9) for the HLA-class I-A3 allele, was investigated for the ability to induce cytotoxic T cell activity. T cell lines from different HLA-A2 and HLA-A3 donors were established by in vitro stimulation with PSA-OP; the CTL lines lysed PSA-OP as well as PSA-1- or PSA-3-pulsed C1R-A2 cells, and PSA-OP and PSA-9-pulsed C1R-A3 cells, respectively. The CTL lines derived from the PSA-OP peptide also lysed PSA-positive prostate cancer cells. PSA-OP-derived T cell lines also lysed recombinant vaccinia-PSA-infected targets but not targets infected with wild-type vaccinia. PSA-OP did not bind HLA-A2 and HLA-A3 molecules. The decrease in cytotoxicity in the presence of protease inhibitors suggests that the PSA-OP is cleaved into shorter peptides, which in turn can interact with HLA-class I molecules and, as a consequence, induce CTL-mediated lysis. We have also demonstrated that it is possible to induce CTL responses in HLA-A2.1/Kb transgenic mice by immunization with PSA-OP with adjuvant. These studies thus provide evidence that oligopeptides such as PSA-OP may be useful candidates for peptide-based cancer vaccines. SN - 0022-1767 UR - https://www.unboundmedicine.com/medline/citation/9743387/Generation_of_human_cytolytic_T_lymphocyte_lines_directed_against_prostate_specific_antigen__PSA__employing_a_PSA_oligoepitope_peptide_ L2 - http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid=9743387 DB - PRIME DP - Unbound Medicine ER -